|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
HRP20050089B1
(hr)
|
2002-07-29 |
2015-06-19 |
Rigel Pharmaceuticals |
Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
|
|
US20050282814A1
(en)
*
|
2002-10-03 |
2005-12-22 |
Targegen, Inc. |
Vasculostatic agents and methods of use thereof
|
|
AU2003282726B2
(en)
*
|
2002-10-03 |
2010-10-07 |
Targegen, Inc. |
Vasculostatic agents and methods of use thereof
|
|
WO2005012294A1
(en)
*
|
2003-07-30 |
2005-02-10 |
Rigel Pharmaceuticals, Inc. |
2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
|
|
EP2543376A1
(en)
*
|
2004-04-08 |
2013-01-09 |
Targegen, Inc. |
Benzotriazine inhibitors of kinases
|
|
US7652051B2
(en)
|
2004-08-25 |
2010-01-26 |
Targegen, Inc. |
Heterocyclic compounds and methods of use
|
|
AU2006206458B2
(en)
|
2005-01-19 |
2012-10-25 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
|
BRPI0610876B8
(pt)
|
2005-06-08 |
2021-05-25 |
Rigel Pharmaceuticals Inc |
composto, formulação farmacêutica, e métodos de inibir uma atividade de uma jak cinase, e de inibir uma cascata de transdução de sinal em que jak3 cinase desempenha um papel
|
|
AU2006254825A1
(en)
*
|
2005-06-08 |
2006-12-14 |
Targegen, Inc. |
Methods and compositions for the treatment of ocular disorders
|
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
US8133900B2
(en)
|
2005-11-01 |
2012-03-13 |
Targegen, Inc. |
Use of bi-aryl meta-pyrimidine inhibitors of kinases
|
|
US8604042B2
(en)
|
2005-11-01 |
2013-12-10 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
|
JP5191391B2
(ja)
|
2005-11-01 |
2013-05-08 |
ターゲジェン インコーポレーティッド |
キナーゼのビ−アリールメタ−ピリミジン阻害剤
|
|
WO2007056075A2
(en)
*
|
2005-11-02 |
2007-05-18 |
Targegen, Inc. |
Six membered heteroaromatic inhibitors targeting resistant kinase mutations
|
|
SG10202003901UA
(en)
|
2005-12-13 |
2020-05-28 |
Incyte Holdings Corp |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
|
|
ES2622493T3
(es)
|
2006-02-24 |
2017-07-06 |
Rigel Pharmaceuticals, Inc. |
Composiciones y métodos para la inhibición de la ruta de JAK
|
|
US7691858B2
(en)
*
|
2006-04-25 |
2010-04-06 |
Targegen, Inc. |
Kinase inhibitors and methods of use thereof
|
|
WO2008008234A1
(en)
*
|
2006-07-07 |
2008-01-17 |
Targegen, Inc. |
2-amino-5-substituted pyrimidine inhibitors
|
|
ES2555803T3
(es)
|
2006-10-23 |
2016-01-08 |
Cephalon, Inc. |
Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met
|
|
BRPI0721138A2
(pt)
|
2006-12-22 |
2014-04-01 |
Hoffmann La Roche |
Derivados de espiro-piperidina
|
|
TW200840581A
(en)
*
|
2007-02-28 |
2008-10-16 |
Astrazeneca Ab |
Novel pyrimidine derivatives
|
|
JP2010520222A
(ja)
*
|
2007-03-01 |
2010-06-10 |
スーパージェン， インコーポレイテッド |
ピリミジン−２，４−ジアミン誘導体およびｊａｋ２キナーゼ阻害剤としてのピリミジン−２，４−ジアミン誘導体の使用
|
|
WO2008118822A1
(en)
*
|
2007-03-23 |
2008-10-02 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
KR20150036210A
(ko)
|
2007-06-13 |
2015-04-07 |
인사이트 코포레이션 |
야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
|
|
EA201000101A1
(ru)
*
|
2007-07-16 |
2010-08-30 |
Астразенека Аб |
Производные пиримидина 934
|
|
CN101903357A
(zh)
|
2007-07-17 |
2010-12-01 |
里格尔药品股份有限公司 |
作为pkc抑制剂的环状胺取代的嘧啶二胺
|
|
EA017252B1
(ru)
|
2007-08-28 |
2012-11-30 |
Айрм Ллк |
Производные 2-бифениламино-4-аминопиримидина в качестве ингибиторов киназ
|
|
EP2219671A4
(en)
*
|
2007-11-09 |
2011-02-09 |
Salk Inst For Biological Studi |
USE OF TAM RECEPTOR INHIBITORS AS IMMU ENHANCERS AND TAM ACTIVATORS AS IMMUNOSUPPRESSORS
|
|
US20100310563A1
(en)
*
|
2007-11-30 |
2010-12-09 |
Bumm Thomas G P |
Methods for treating induced cellular proliferative disorders
|
|
WO2009087127A1
(en)
|
2008-01-11 |
2009-07-16 |
F. Hoffmann-La Roche Ag |
Modulators for amyloid beta
|
|
JP5328816B2
(ja)
|
2008-02-22 |
2013-10-30 |
エフ．ホフマン−ラ ロシュ アーゲー |
アミロイドβの調節薬
|
|
MX2010009159A
(es)
|
2008-02-22 |
2010-09-14 |
Rigel Pharmaceuticals Inc |
Uso de 2,4-pirimidindiaminas para el tratamiento de aterosclerosis.
|
|
US20090275529A1
(en)
*
|
2008-05-05 |
2009-11-05 |
Reiss Allison B |
Method for improving cardiovascular risk profile of cox inhibitors
|
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
|
MX353308B
(es)
|
2008-05-21 |
2018-01-08 |
Ariad Pharma Inc |
Derivados fosforosos como inhibidores de cinasa.
|
|
PE20100087A1
(es)
|
2008-06-25 |
2010-02-08 |
Irm Llc |
Compuestos y composiciones como inhibidores de cinasa
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
NZ603525A
(en)
*
|
2008-06-27 |
2015-02-27 |
Celgene Avilomics Res Inc |
Pyrimidine based compound and uses thereof
|
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
WO2010011349A2
(en)
*
|
2008-07-25 |
2010-01-28 |
Supergen, Inc. |
Pyrimidine-2,4-diamine jak2 kinase inhibiting anti-inflammation use
|
|
AU2009279825A1
(en)
*
|
2008-08-05 |
2010-02-11 |
Targegen, Inc. |
Methods of treating thalassemia
|
|
CL2009001884A1
(es)
*
|
2008-10-02 |
2010-05-14 |
Incyte Holdings Corp |
Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
|
|
WO2010040661A1
(en)
|
2008-10-09 |
2010-04-15 |
F. Hoffmann-La Roche Ag |
Modulators for amyloid beta
|
|
AU2009312856A1
(en)
|
2008-11-10 |
2010-05-14 |
F. Hoffmann-La Roche Ag |
Heterocyclic gamma secretase modulators
|
|
US20110245156A1
(en)
*
|
2008-12-09 |
2011-10-06 |
Cytokine Pharmasciences, Inc. |
Novel antiviral compounds, compositions, and methods of use
|
|
WO2010093808A1
(en)
|
2009-02-11 |
2010-08-19 |
Reaction Biology Corp. |
Selective kinase inhibitors
|
|
CA2757671A1
(en)
*
|
2009-04-03 |
2010-10-07 |
Cellzome Ag |
Methods for the identification of kinase interacting molecules and for the purification of kinase proteins
|
|
CA2758614A1
(en)
*
|
2009-04-14 |
2010-10-21 |
Cellzome Limited |
Fluoro substituted pyrimidine compounds as jak3 inhibitors
|
|
US9908884B2
(en)
|
2009-05-05 |
2018-03-06 |
Dana-Farber Cancer Institute, Inc. |
EGFR inhibitors and methods of treating disorders
|
|
US8367689B2
(en)
*
|
2009-05-06 |
2013-02-05 |
Portola Pharmaceuticals, Inc. |
Inhibitors of JAK
|
|
SI2432472T1
(sl)
*
|
2009-05-22 |
2019-11-29 |
Incyte Holdings Corp |
3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK
|
|
AR076794A1
(es)
|
2009-05-22 |
2011-07-06 |
Incyte Corp |
Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
|
|
KR101763656B1
(ko)
|
2009-06-29 |
2017-08-01 |
인사이트 홀딩스 코포레이션 |
Ｐｉ3ｋ 저해물질로서의 피리미디논
|
|
JP2012197231A
(ja)
*
|
2009-08-06 |
2012-10-18 |
Oncotherapy Science Ltd |
Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
|
|
TW201113285A
(en)
|
2009-09-01 |
2011-04-16 |
Incyte Corp |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
|
NZ598985A
(en)
*
|
2009-09-04 |
2013-07-26 |
Biogen Idec Inc |
Bruton's tyrosine kinase inhibitors
|
|
US20120172385A1
(en)
*
|
2009-09-11 |
2012-07-05 |
Richard John Harrison |
Ortho substituted pyrimidine compounds as jak inhibitors
|
|
US9556426B2
(en)
|
2009-09-16 |
2017-01-31 |
Celgene Avilomics Research, Inc. |
Protein kinase conjugates and inhibitors
|
|
ES2426407T3
(es)
|
2009-10-15 |
2013-10-23 |
Pfizer Inc. |
Compuestos de pirrolo[2,3-d]pirimidina
|
|
EA021439B1
(ru)
|
2009-11-03 |
2015-06-30 |
ГЛЭКСОСМИТКЛАЙН ЭлЭлСи |
Хиназолиновые соединения
|
|
WO2011056739A1
(en)
*
|
2009-11-03 |
2011-05-12 |
Glaxosmithkline Llc |
Compounds and methods
|
|
RU2012129887A
(ru)
*
|
2009-12-14 |
2014-01-27 |
Мсд Осс Б.В. |
Ингибиторы мк2
|
|
WO2011075334A1
(en)
|
2009-12-18 |
2011-06-23 |
Pfizer Inc. |
Pyrrolo[2,3-d]pyrimidine compounds
|
|
US8759359B2
(en)
|
2009-12-18 |
2014-06-24 |
Incyte Corporation |
Substituted heteroaryl fused derivatives as PI3K inhibitors
|
|
WO2011076878A1
(en)
*
|
2009-12-23 |
2011-06-30 |
Palau Pharma, S.A. |
Aminoalkylpyrimidine derivatives as histamine h4 receptor antagonists
|
|
JP2013516422A
(ja)
|
2009-12-30 |
2013-05-13 |
アビラ セラピューティクス， インコーポレイテッド |
タンパク質のリガンド−指向性共有的修飾
|
|
KR20120114355A
(ko)
*
|
2010-01-13 |
2012-10-16 |
글락소스미스클라인 엘엘씨 |
화합물 및 방법
|
|
US8486967B2
(en)
|
2010-02-17 |
2013-07-16 |
Hoffmann-La Roche Inc. |
Heteroaryl substituted piperidines
|
|
EP3354652B1
(en)
|
2010-03-10 |
2020-05-06 |
Incyte Holdings Corporation |
Piperidin-4-yl azetidine derivatives as jak1 inhibitors
|
|
KR101461767B1
(ko)
|
2010-03-30 |
2014-11-13 |
노파르티스 아게 |
만성 활성 ｂ-세포-수용체 신호전달이 있는 ｂ-세포 림프종의 치료를 위한 ｐｋｃ 억제제
|
|
EP2558463A1
(en)
|
2010-04-14 |
2013-02-20 |
Incyte Corporation |
Fused derivatives as i3 inhibitors
|
|
MX354217B
(es)
|
2010-05-14 |
2018-02-19 |
Dana Farber Cancer Inst Inc |
Composiciones y metodos para el tratamiento de leucemia.
|
|
PL2902030T3
(pl)
|
2010-05-14 |
2017-07-31 |
Dana-Farber Cancer Institute, Inc. |
Związki tienotriazolodiazepinowe do leczenia nowotworu
|
|
EP2571875A4
(en)
|
2010-05-14 |
2013-10-30 |
Dana Farber Cancer Inst Inc |
CONTRACEPTIVE COMPOSITIONS FOR MEN AND METHODS OF USE THEREOF
|
|
US8927547B2
(en)
|
2010-05-21 |
2015-01-06 |
Noviga Research Ab |
Pyrimidine derivatives
|
|
PE20130216A1
(es)
|
2010-05-21 |
2013-02-27 |
Incyte Corp |
Formulacion topica para un inhibidor de jak
|
|
WO2011149827A1
(en)
*
|
2010-05-24 |
2011-12-01 |
Glaxosmithkline Llc |
Compounds and methods
|
|
MX336875B
(es)
|
2010-08-10 |
2016-02-04 |
Celgene Avilomics Res Inc |
Sal de besilato de un inhibidor de tirosina cinasa de bruton (btk).
|
|
EP2635284B1
(en)
|
2010-11-01 |
2019-12-18 |
Celgene CAR LLC |
Heterocyclic compounds and uses thereof
|
|
WO2012061303A1
(en)
|
2010-11-01 |
2012-05-10 |
Avila Therapeutics, Inc. |
Heteroaryl compounds and uses thereof
|
|
AU2010363329A1
(en)
*
|
2010-11-07 |
2013-05-09 |
Targegen, Inc. |
Compositions and methods for treating myelofibrosis
|
|
WO2012064706A1
(en)
|
2010-11-10 |
2012-05-18 |
Avila Therapeutics, Inc. |
Mutant-selective egfr inhibitors and uses thereof
|
|
US9034884B2
(en)
|
2010-11-19 |
2015-05-19 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
|
|
PE20140146A1
(es)
|
2010-11-19 |
2014-02-06 |
Incyte Corp |
Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
|
|
EP3660016A1
(en)
|
2010-12-20 |
2020-06-03 |
Incyte Holdings Corporation |
N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
|
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
|
US9108984B2
(en)
*
|
2011-03-14 |
2015-08-18 |
Incyte Corporation |
Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
|
|
DK2688883T3
(en)
|
2011-03-24 |
2016-09-05 |
Noviga Res Ab |
pyrimidine
|
|
WO2012135009A1
(en)
*
|
2011-03-25 |
2012-10-04 |
Incyte Corporation |
Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
|
|
WO2012135641A2
(en)
|
2011-03-30 |
2012-10-04 |
H. Lee Moffitt Cancer Center And Research Institute |
Aurora kinase inhibitors and methods of making and using thereof
|
|
JP6147727B2
(ja)
|
2011-04-01 |
2017-06-14 |
ユニヴァーシティー オブ ユタ リサーチ ファウンデーション |
チロシン受容体キナーゼｂｔｋ阻害剤としての置換ｎ−（３−（ピリミジン−４−イル）フェニル）アクリルアミド類似体
|
|
ES2759615T3
(es)
*
|
2011-04-01 |
2020-05-11 |
Univ Utah Res Found |
Análogos de N-fenilpirimidina-2-amina sustituidos como inhibidores de la quinasa AXL
|
|
EP2704572B1
(en)
|
2011-05-04 |
2015-12-30 |
Ariad Pharmaceuticals, Inc. |
Compounds for inhibiting cell proliferation in egfr-driven cancers
|
|
CN103797010B
(zh)
|
2011-06-20 |
2016-02-24 |
因塞特控股公司 |
作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
|
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
|
|
PT3513793T
(pt)
|
2011-09-02 |
2021-05-10 |
Incyte Holdings Corp |
Heterociclilaminas como inibidores de pi3k
|
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
|
WO2013059548A1
(en)
|
2011-10-19 |
2013-04-25 |
Sanofi |
Compositions and methods for treating cancer using jak2 inhibitor
|
|
US9364476B2
(en)
|
2011-10-28 |
2016-06-14 |
Celgene Avilomics Research, Inc. |
Methods of treating a Bruton's Tyrosine Kinase disease or disorder
|
|
CN102429901B
(zh)
*
|
2011-11-03 |
2013-11-06 |
合肥博太医药生物技术发展有限公司 |
吲哚-3-甲醇、二吲哚甲烷及其衍生物在制备防治肾纤维化药物中的应用
|
|
CA2866852C
(en)
|
2012-03-15 |
2020-12-29 |
Celgene Avilomics Research, Inc. |
Solid forms of an epidermal growth factor receptor kinase inhibitor
|
|
BR112014022790B1
(pt)
|
2012-03-15 |
2022-04-19 |
Celgene Car Llc |
Sais de um inibidor de quinase de receptor de fator do crescimento epidermal, composição farmacêutica e usos do mesmo
|
|
AR090548A1
(es)
|
2012-04-02 |
2014-11-19 |
Incyte Corp |
Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
|
|
WO2013169401A1
(en)
|
2012-05-05 |
2013-11-14 |
Ariad Pharmaceuticals, Inc. |
Compounds for inhibiting cell proliferation in egfr-driven cancers
|
|
TW201406761A
(zh)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
|
|
AR091273A1
(es)
|
2012-06-08 |
2015-01-21 |
Biogen Idec Inc |
Inhibidores de pirimidinil tirosina quinasa
|
|
US9353087B2
(en)
|
2012-06-08 |
2016-05-31 |
Biogen Ma Inc. |
Inhibitors of Bruton's tyrosine kinase
|
|
RS58514B1
(sr)
|
2012-06-13 |
2019-04-30 |
Incyte Holdings Corp |
Supstituisana triciklična jedinjenja kao inhibitori fgfr
|
|
JP6280546B2
(ja)
|
2012-06-26 |
2018-02-14 |
デル マー ファーマシューティカルズ |
ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
CA2887465A1
(en)
|
2012-10-04 |
2014-04-10 |
University Of Utah Research Foundation |
Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
|
|
WO2014055928A2
(en)
|
2012-10-04 |
2014-04-10 |
University Of Utah Research Foundation |
Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
|
|
PH12020551186B1
(en)
|
2012-11-15 |
2024-03-20 |
Incyte Holdings Corp |
Sustained-release dosage forms of ruxolitinib
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
US9126950B2
(en)
|
2012-12-21 |
2015-09-08 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
MX2015009952A
(es)
|
2013-02-08 |
2015-10-05 |
Celgene Avilomics Res Inc |
Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos.
|
|
RS62867B1
(sr)
|
2013-03-06 |
2022-02-28 |
Incyte Holdings Corp |
Postupci i intermedijeri za dobijanje inhibitora jak
|
|
WO2014159392A1
(en)
|
2013-03-14 |
2014-10-02 |
Dana-Farber Cancer Institute, Inc. |
Bromodomain binding reagents and uses thereof
|
|
MX394360B
(es)
|
2013-03-14 |
2025-03-24 |
Sumitomo Pharma Oncology Inc |
Inhibidores de jak2 y alk2 y metodos para su uso.
|
|
US9834521B2
(en)
|
2013-03-15 |
2017-12-05 |
Ariad Pharmaceuticals, Inc. |
Choline kinase inhibitors
|
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
|
US9210831B2
(en)
|
2013-04-15 |
2015-12-08 |
International Business Machines Corporation |
Separable and integrated heat sinks facilitating cooling multi-compnent electronic assembly
|
|
PH12015502383B1
(en)
|
2013-04-19 |
2023-02-03 |
Incyte Holdings Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
NO3004079T3
(https=)
*
|
2013-06-04 |
2018-06-16 |
|
|
|
US9975896B2
(en)
|
2013-07-25 |
2018-05-22 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of transcription factors and uses thereof
|
|
EP3030241A4
(en)
*
|
2013-08-06 |
2019-06-19 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
INHIBITORS OF ACK1 / TNK2.TYROSINE KINASE
|
|
SMT202000315T1
(it)
|
2013-08-07 |
2020-07-08 |
Incyte Corp |
Forme di dosaggio a rilascio prolungato per un inibitore di jak1
|
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
|
RU2016122654A
(ru)
|
2013-11-08 |
2017-12-14 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка
|
|
AU2014362231B2
(en)
|
2013-12-11 |
2019-04-04 |
Biogen Ma Inc. |
Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
|
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
CN105940005A
(zh)
|
2014-01-31 |
2016-09-14 |
达纳-法伯癌症研究所股份有限公司 |
二氮杂环庚烷衍生物及其用途
|
|
EP3099677A4
(en)
|
2014-01-31 |
2017-07-26 |
Dana-Farber Cancer Institute, Inc. |
Diaminopyrimidine benzenesulfone derivatives and uses thereof
|
|
US10793571B2
(en)
|
2014-01-31 |
2020-10-06 |
Dana-Farber Cancer Institute, Inc. |
Uses of diazepane derivatives
|
|
WO2015131080A1
(en)
|
2014-02-28 |
2015-09-03 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
JP2017506666A
(ja)
|
2014-02-28 |
2017-03-09 |
テンシャ セラピューティクス，インコーポレイテッド |
高インスリン血症に関連した症状の処置
|
|
US9498467B2
(en)
|
2014-05-30 |
2016-11-22 |
Incyte Corporation |
Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
|
|
WO2015191677A1
(en)
|
2014-06-11 |
2015-12-17 |
Incyte Corporation |
Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
|
|
WO2016022460A1
(en)
*
|
2014-08-03 |
2016-02-11 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Potent dual brd4-kinase inhibitors as cancer therapeutics
|
|
CN106793775B
(zh)
|
2014-08-08 |
2020-06-02 |
达纳-法伯癌症研究所股份有限公司 |
二氢碟啶酮衍生物及其用途
|
|
CN106715437A
(zh)
|
2014-08-08 |
2017-05-24 |
达纳-法伯癌症研究所股份有限公司 |
二氮杂环庚烷衍生物及其用途
|
|
CN117088931A
(zh)
|
2014-08-12 |
2023-11-21 |
莫纳什大学 |
定向淋巴的前药
|
|
EP3179858B1
(en)
|
2014-08-13 |
2019-05-15 |
Celgene Car Llc |
Forms and compositions of an erk inhibitor
|
|
TWI679205B
(zh)
*
|
2014-09-02 |
2019-12-11 |
日商日本新藥股份有限公司 |
吡唑并噻唑化合物及醫藥
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
KR20170068597A
(ko)
|
2014-10-27 |
2017-06-19 |
텐샤 세러퓨틱스 인코포레이티드 |
브로모도메인 저해제
|
|
WO2016068867A1
(en)
|
2014-10-28 |
2016-05-06 |
Cummins Emission Solutions, Inc. |
Scr conversion efficiency diagnostics
|
|
CN107148425B
(zh)
|
2014-10-29 |
2021-08-03 |
拜斯科阿迪有限公司 |
对mt1-mmp特异性的双环肽配体
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
TWI712601B
(zh)
|
2015-02-20 |
2020-12-11 |
美商英塞特公司 |
作為fgfr抑制劑之雙環雜環
|
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
TWI788655B
(zh)
|
2015-02-27 |
2023-01-01 |
美商林伯士拉克許米公司 |
酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途
|
|
SG10201907576SA
(en)
|
2015-02-27 |
2019-09-27 |
Incyte Corp |
Salts of pi3k inhibitor and processes for their preparation
|
|
US9988401B2
(en)
|
2015-05-11 |
2018-06-05 |
Incyte Corporation |
Crystalline forms of a PI3K inhibitor
|
|
US9732097B2
(en)
|
2015-05-11 |
2017-08-15 |
Incyte Corporation |
Process for the synthesis of a phosphoinositide 3-kinase inhibitor
|
|
WO2016201370A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
|
WO2017004134A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
WO2017012559A1
(zh)
*
|
2015-07-21 |
2017-01-26 |
广州再极医药科技有限公司 |
稠环嘧啶类化合物、中间体、其制备方法、组合物和应用
|
|
TWI707852B
(zh)
|
2015-09-02 |
2020-10-21 |
美商林伯士拉克許米公司 |
Tyk2 抑制劑及其用途
|
|
US11738087B2
(en)
|
2015-09-08 |
2023-08-29 |
Monash University |
Lymph directing prodrugs
|
|
EP3347021A4
(en)
|
2015-09-11 |
2019-07-24 |
Dana-Farber Cancer Institute, Inc. |
CYANOTHIENOTRIAZOLDIAZEPINE AND USES THEREOF
|
|
RU2018112953A
(ru)
|
2015-09-11 |
2019-10-14 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Ацетамидтиенотриазолодиазепины и пути их применения
|
|
US10683308B2
(en)
|
2015-09-11 |
2020-06-16 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
|
WO2017066428A1
(en)
|
2015-10-13 |
2017-04-20 |
H. Lee Moffitt Cancer Center & Research Institute, Inc. |
Brd4-kinase inhibitors as cancer therapeutics
|
|
AU2016342027B2
(en)
|
2015-10-23 |
2021-05-13 |
Navitor Pharmaceuticals, Inc. |
Modulators of Sestrin-GATOR2 interaction and uses thereof
|
|
US10045981B2
(en)
|
2015-11-24 |
2018-08-14 |
Jakpharm, Llc |
Selective kinase inhibitors
|
|
MX2018006499A
(es)
|
2015-11-25 |
2018-08-01 |
Dana Farber Cancer Inst Inc |
Inhibidores de bromodominio bivalentes y usos de los mismos.
|
|
GB201521919D0
(en)
|
2015-12-11 |
2016-01-27 |
Electrophoretics Ltd |
Isobaric mass labels
|
|
EP3389664A4
(en)
|
2015-12-14 |
2020-01-08 |
Raze Therapeutics Inc. |
MTHFD2 CAFFEIN INHIBITORS AND USES THEREOF
|
|
EP4234552A3
(en)
|
2016-03-09 |
2023-10-18 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
|
DK3426243T3
(da)
|
2016-03-09 |
2021-07-19 |
Raze Therapeutics Inc |
3-phosphoglyceratdehydrogenase-inhibitorer og anvendelser deraf
|
|
CA3019394A1
(en)
|
2016-04-08 |
2017-10-12 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
|
PL3442947T3
(pl)
*
|
2016-04-15 |
2023-10-02 |
Epizyme, Inc. |
Związki arylowe lub heteroarylowe podstawione aminą jako inhibitory ehmt1 i ehmt2
|
|
ES2870920T3
(es)
|
2016-06-21 |
2021-10-28 |
X4 Pharmaceuticals Inc |
Inhibidores de CXCR4 y usos de los mismos
|
|
CN109640988A
(zh)
|
2016-06-21 |
2019-04-16 |
X4 制药有限公司 |
Cxcr4抑制剂及其用途
|
|
EP3472129A4
(en)
|
2016-06-21 |
2019-12-04 |
X4 Pharmaceuticals, Inc. |
CXCR4 INHIBITORS AND USES THEREOF
|
|
JP7214632B2
(ja)
|
2016-07-21 |
2023-01-30 |
バイオジェン エムエー インク． |
ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物
|
|
US10323036B2
(en)
|
2016-10-14 |
2019-06-18 |
Nimbus Lakshmi, Inc. |
TYK2 inhibitors and uses thereof
|
|
EP3528816A4
(en)
|
2016-10-21 |
2020-04-08 |
Nimbus Lakshmi, Inc. |
TYK2 INHIBITORS AND USES THEREOF
|
|
WO2018089499A1
(en)
|
2016-11-08 |
2018-05-17 |
Navitor Pharmaceuticals, Inc. |
PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
|
|
CA3043768A1
(en)
|
2016-11-29 |
2018-06-07 |
PureTech Health LLC |
Exosomes for delivery of therapeutic agents
|
|
US11091451B2
(en)
|
2016-12-05 |
2021-08-17 |
Raze Therapeutics, Inc. |
SHMT inhibitors and uses thereof
|
|
WO2018115203A1
(en)
|
2016-12-23 |
2018-06-28 |
Bicyclerd Limited |
Peptide derivatives having novel linkage structures
|
|
US10624968B2
(en)
|
2017-01-06 |
2020-04-21 |
Bicyclerd Limited |
Compounds for treating cancer
|
|
TW202515876A
(zh)
|
2017-03-08 |
2025-04-16 |
日商武田藥品工業股份有限公司 |
Tyk2抑制劑及其用途
|
|
EP3375784A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aza-dihydro-acridone derivatives
|
|
EP3375778A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aryl-piperidine derivatives
|
|
US10342766B2
(en)
*
|
2017-03-23 |
2019-07-09 |
North Carolina Agricultural And Technical State University |
6-shogaol derivatives and activities thereof
|
|
WO2018191146A1
(en)
|
2017-04-10 |
2018-10-18 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl rheb inhibitors and uses thereof
|
|
CN110621316B
(zh)
|
2017-04-21 |
2024-01-26 |
Epizyme股份有限公司 |
用ehmt2抑制剂进行的组合疗法
|
|
PL3615019T3
(pl)
|
2017-04-26 |
2026-01-19 |
Navitor Pharmaceuticals, Inc. |
Modulator interakcji sestryna-gator2 do zastosowania w leczeniu depresji opornej na leczenie
|
|
US10857196B2
(en)
|
2017-04-27 |
2020-12-08 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
EP3645549A1
(en)
|
2017-06-26 |
2020-05-06 |
BicycleRD Limited |
Bicyclic peptide ligands with detectable moieties and uses thereof
|
|
SI3658557T1
(sl)
|
2017-07-28 |
2024-10-30 |
Takeda Pharmaceutical Company Limited |
Zaviralci TYK2 in njihova uporaba
|
|
JP7670481B2
(ja)
|
2017-08-04 |
2025-04-30 |
バイスクルテクス・リミテッド |
Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
|
|
WO2019034868A1
(en)
|
2017-08-14 |
2019-02-21 |
Bicyclerd Limited |
CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF
|
|
WO2019034866A1
(en)
|
2017-08-14 |
2019-02-21 |
Bicyclerd Limited |
BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
|
|
US11883497B2
(en)
|
2017-08-29 |
2024-01-30 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
|
CA3077739A1
(en)
|
2017-08-29 |
2019-03-07 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
|
WO2019060742A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc |
AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
|
|
US11358948B2
(en)
|
2017-09-22 |
2022-06-14 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
JP2021500334A
(ja)
*
|
2017-10-18 |
2021-01-07 |
エピザイム，インコーポレイティド |
Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物、その塩、及びそれらの合成方法
|
|
WO2019113487A1
(en)
|
2017-12-08 |
2019-06-13 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
|
GB201721265D0
(en)
|
2017-12-19 |
2018-01-31 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for EphA2
|
|
TWI825046B
(zh)
|
2017-12-19 |
2023-12-11 |
英商拜西可泰克斯有限公司 |
Epha2特用之雙環胜肽配位基
|
|
US11304954B2
(en)
|
2017-12-19 |
2022-04-19 |
Puretech Lyt, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
|
EP3727362A4
(en)
|
2017-12-19 |
2021-10-06 |
PureTech LYT, Inc. |
MYCOPHENOLIC ACID LIPID PRODRUGS AND THEIR USES
|
|
US11608345B1
(en)
|
2017-12-19 |
2023-03-21 |
Puretech Lyt, Inc. |
Lipid prodrugs of rapamycin and its analogs and uses thereof
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
CN111892543A
(zh)
*
|
2018-01-16 |
2020-11-06 |
深圳市塔吉瑞生物医药有限公司 |
用于抑制激酶活性的二苯氨基嘧啶类化合物
|
|
BR112020015396A2
(pt)
|
2018-01-29 |
2020-12-08 |
Merck Patent Gmbh |
Inididores de gcn2 e usos dos mesmos
|
|
JP7229257B2
(ja)
|
2018-01-29 |
2023-02-28 |
メルク パテント ゲーエムベーハー |
Ｇｃｎ２阻害剤およびその使用
|
|
SG11202007164UA
(en)
|
2018-01-30 |
2020-08-28 |
Incyte Corp |
Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
|
|
WO2019152883A1
(en)
*
|
2018-02-02 |
2019-08-08 |
Padforward Llc |
Inhibitors of protein arginine deiminases
|
|
CN111902429A
(zh)
|
2018-02-23 |
2020-11-06 |
拜斯科技术开发有限公司 |
多聚体双环肽配体
|
|
EP3759086A1
(en)
|
2018-02-27 |
2021-01-06 |
Artax Biopharma Inc. |
Chromene derivatives as inhibitors of tcr-nck interaction
|
|
SMT202400306T1
(it)
|
2018-03-30 |
2024-09-16 |
Incyte Corp |
Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak.
|
|
KR20210003780A
(ko)
|
2018-04-05 |
2021-01-12 |
스미토모 다이니폰 파마 온콜로지, 인크. |
Axl 키나제 억제제 및 그의 용도
|
|
KR102063155B1
(ko)
|
2018-04-11 |
2020-01-08 |
한국과학기술연구원 |
우수한 카이네이즈 저해 활성을 보이는 다양한 치환기를 갖는 피리미딘 유도체
|
|
ES2969982T3
(es)
|
2018-04-24 |
2024-05-23 |
Vertex Pharma |
Compuestos de pteridinona y usos de los mismos
|
|
HRP20241163T1
(hr)
|
2018-04-24 |
2024-11-22 |
Merck Patent Gmbh |
Antiproliferacijski spojevi i njihova uporaba
|
|
HRP20241288T1
(hr)
|
2018-05-04 |
2024-12-06 |
Incyte Corporation |
Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
|
|
AU2019262579B2
(en)
|
2018-05-04 |
2024-09-12 |
Incyte Corporation |
Salts of an FGFR inhibitor
|
|
SG11202011680YA
(en)
|
2018-06-01 |
2020-12-30 |
Incyte Corp |
Dosing regimen for the treatment of pi3k related disorders
|
|
WO2019241789A1
(en)
|
2018-06-15 |
2019-12-19 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
|
IL279489B2
(en)
|
2018-06-22 |
2025-10-01 |
Bicycletx Ltd |
Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
|
|
GB201810316D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicyclerd Ltd |
Peptide ligands for binding to EphA2
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
|
AU2019310590A1
(en)
|
2018-07-26 |
2021-01-14 |
Sumitomo Pharma Oncology, Inc. |
Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
|
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
|
WO2020051424A1
(en)
|
2018-09-07 |
2020-03-12 |
Pic Therapeutics |
Eif4e inhibitors and uses thereof
|
|
BR112021005518A2
(pt)
*
|
2018-09-25 |
2021-06-29 |
Impact Biomedicines, Inc. |
métodos para tratar distúrbios mieloproliferativos
|
|
CN113271940A
(zh)
|
2018-10-15 |
2021-08-17 |
林伯士拉克许米公司 |
Tyk2抑制剂和其用途
|
|
WO2020084305A1
(en)
|
2018-10-23 |
2020-04-30 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
|
EP3870158A4
(en)
|
2018-10-24 |
2022-08-10 |
Navitor Pharmaceuticals, Inc. |
Polymorphic compounds and uses thereof
|
|
WO2020092015A1
(en)
*
|
2018-11-02 |
2020-05-07 |
University Of Rochester |
Therapeutic mitigation of epithelial infection
|
|
CA3120866A1
(en)
|
2018-11-30 |
2020-06-04 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
CA3119773A1
(en)
|
2018-11-30 |
2020-06-04 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
GB201820288D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicycle Tx Ltd |
Bicycle peptide ligaands specific for MT1-MMP
|
|
GB201820295D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for MT1-MMP
|
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
|
WO2020128527A1
(en)
|
2018-12-21 |
2020-06-25 |
Bicyclerd Limited |
Bicyclic peptide ligands specific for pd-l1
|
|
US12492224B2
(en)
|
2018-12-21 |
2025-12-09 |
Bicycletx Limited |
Bicyclic peptide ligands specific for PD-L1
|
|
CN111362922A
(zh)
*
|
2018-12-26 |
2020-07-03 |
上海喆邺生物科技有限公司 |
2,4-二氨基嘧啶衍生物及其用途
|
|
CN113348021B
(zh)
|
2019-01-23 |
2025-07-11 |
武田药品工业株式会社 |
Tyk2抑制剂和其用途
|
|
FR3092581A1
(fr)
*
|
2019-02-12 |
2020-08-14 |
Impact Biomedicines, Inc |
Formes cristallines d'un inhibiteur de jak2
|
|
US12559463B2
(en)
|
2019-02-12 |
2026-02-24 |
Impact Biomedicines Inc. |
Crystalline forms of a JAK2 inhibitor
|
|
WO2020165600A1
(en)
|
2019-02-14 |
2020-08-20 |
Bicycletx Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
|
KR102866499B1
(ko)
*
|
2019-03-15 |
2025-10-02 |
더 제너럴 하스피탈 코포레이션 |
Tead 전사인자의 신규한 소분자 저해제
|
|
SG11202110828UA
(en)
|
2019-04-02 |
2021-10-28 |
Bicycletx Ltd |
Bicycle toxin conjugates and uses thereof
|
|
CN120574283A
(zh)
|
2019-04-05 |
2025-09-02 |
凯麦拉医疗公司 |
Stat降解剂和其用途
|
|
CA3141826A1
(en)
|
2019-05-31 |
2020-12-03 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
WO2020251972A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
WO2020256739A1
(en)
|
2019-06-21 |
2020-12-24 |
Constellation Pharmaceuticals, Inc. |
Methods of treating myeloproliferative disorders
|
|
WO2020257644A1
(en)
|
2019-06-21 |
2020-12-24 |
Constellation Pharmaceuticals, Inc. |
Methods of treating myeloproliferative disorders
|
|
WO2021091535A1
(en)
|
2019-11-05 |
2021-05-14 |
Constellation Pharmaceuticals, Inc. |
Treating myeloproliferative disorders with cpi-0610 and a jak inhibitor
|
|
PH12022500002A1
(en)
|
2019-06-28 |
2023-04-03 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2021011868A1
(en)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
TWI860386B
(zh)
|
2019-07-30 |
2024-11-01 |
英商拜西可泰克斯有限公司 |
異質雙環肽複合物
|
|
US11845724B2
(en)
|
2019-09-11 |
2023-12-19 |
Vincere Biosciences, Inc. |
USP30 inhibitors and uses thereof
|
|
MX2022002877A
(es)
|
2019-09-13 |
2022-08-08 |
Nimbus Saturn Inc |
Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
|
|
US20220372135A1
(en)
|
2019-09-27 |
2022-11-24 |
Disc Medicine, Inc. |
Methods for treating myelofibrosis and related conditions
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CA3157361A1
(en)
|
2019-10-14 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
US11306062B2
(en)
|
2019-10-29 |
2022-04-19 |
Johnson Matthey Public Limited |
Forms of fedratinib dihydrochloride
|
|
US11723890B2
(en)
|
2019-11-01 |
2023-08-15 |
Navitor Pharmaceuticals, Inc. |
Methods of treatment using an mTORC1 modulator
|
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
JP7832891B2
(ja)
|
2019-12-04 |
2026-03-18 |
インサイト・コーポレイション |
Ｆｇｆｒ阻害剤の誘導体
|
|
AU2020397938A1
(en)
|
2019-12-05 |
2022-06-23 |
Janssen Pharmaceutica Nv |
Rapamycin analogs and uses thereof
|
|
WO2021119159A1
(en)
|
2019-12-10 |
2021-06-17 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
KR20220145325A
(ko)
|
2019-12-17 |
2022-10-28 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Irak 분해제 및 이의 용도
|
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
|
WO2021133917A1
(en)
|
2019-12-23 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Smarca inhibitors and uses thereof
|
|
EP4081308A4
(en)
|
2019-12-23 |
2024-01-24 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
CN111423419B
(zh)
*
|
2020-01-17 |
2021-12-17 |
温州医科大学 |
一种小分子化合物cyy-260及其在制备抗肿瘤药物中的应用
|
|
IL295362A
(en)
|
2020-02-05 |
2022-10-01 |
Puretech Lyt Inc |
Lipid drug inhibitors of neurosteroids
|
|
TW202146393A
(zh)
|
2020-03-03 |
2021-12-16 |
美商皮克醫療公司 |
Eif4e抑制劑及其用途
|
|
KR20230005160A
(ko)
|
2020-03-19 |
2023-01-09 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Mdm2 분해제 및 이의 용도
|
|
KR20230012539A
(ko)
|
2020-05-13 |
2023-01-26 |
디스크 메디슨, 인크. |
골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
|
|
US20230250110A1
(en)
|
2020-06-03 |
2023-08-10 |
Kymera Therapeutics, Inc. |
Deuterated irak degraders and uses thereof
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
CN113754591B
(zh)
*
|
2020-06-05 |
2024-01-05 |
山东大学 |
一种hdac、jak和bet三靶点抑制剂及其制备方法和应用
|
|
EP3944859A1
(en)
|
2020-07-30 |
2022-02-02 |
Assistance Publique Hôpitaux de Paris |
Method for treating immune toxicities induced by immune checkpoint inhibitors
|
|
AU2021322934A1
(en)
|
2020-08-03 |
2023-03-30 |
Bicycletx Limited |
Peptide-based linkers
|
|
CA3186504A1
(en)
|
2020-08-17 |
2022-02-24 |
Stephen J. Blakemore |
Bicycle conjugates specific for nectin-4 and uses thereof
|
|
CN112225703B
(zh)
*
|
2020-09-28 |
2022-03-11 |
广州智睿医药科技有限公司 |
一种治疗或预防与lrrk2激酶或异常lrrk2突变激酶活性相关疾病的药物
|
|
US12331046B2
(en)
|
2020-10-23 |
2025-06-17 |
Nimbus Clotho, Inc. |
CTPS1 inhibitors and uses thereof
|
|
EP4238975A4
(en)
*
|
2020-10-29 |
2024-06-12 |
Suzhou Yabao Pharmaceutical R&D Co., Ltd. |
SUBSTITUTED DIARYLAMINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, MANUFACTURING PROCESS THEREOF AND USE THEREOF
|
|
TWI750905B
(zh)
*
|
2020-11-19 |
2021-12-21 |
財團法人國家衛生研究院 |
噻唑化合物作為蛋白質激酶抑制劑
|
|
CA3200814A1
(en)
|
2020-12-02 |
2022-06-09 |
Alfredo C. Castro |
Tead inhibitors and uses thereof
|
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
EP4259144A4
(en)
|
2020-12-09 |
2025-08-20 |
Kymera Therapeutics Inc |
SMARCA DEGRADING AGENTS AND THEIR USES
|
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Ａｌｋ﹘５抑制劑和彼之用途
|
|
US20240058336A1
(en)
|
2020-12-16 |
2024-02-22 |
Impact Biomedicines, Inc. |
Dosing of fedratinib
|
|
CN116710141A
(zh)
*
|
2020-12-29 |
2023-09-05 |
上海岸阔医药科技有限公司 |
预防或治疗抗肿瘤剂相关疾病或病症的方法
|
|
CN116867758A
(zh)
|
2020-12-30 |
2023-10-10 |
凯麦拉医疗公司 |
Irak降解剂和其用途
|
|
CN112778282B
(zh)
*
|
2021-01-06 |
2022-07-22 |
温州医科大学 |
一种嘧啶类小分子化合物及其应用
|
|
MX2023009060A
(es)
|
2021-02-02 |
2023-09-29 |
Liminal Biosciences Ltd |
Antagonistas de gpr84 y usos de estos.
|
|
US12378229B2
(en)
|
2021-02-02 |
2025-08-05 |
Liminal Biosciences Limited |
GPR84 antagonists and uses thereof
|
|
EP4291235A4
(en)
|
2021-02-12 |
2025-01-08 |
Nimbus Saturn, Inc. |
HPK1 ANTAGONISTS AND USES THEREOF
|
|
US12171768B2
(en)
|
2021-02-15 |
2024-12-24 |
Kymera Therapeutics, Inc. |
IRAK4 degraders and uses thereof
|
|
CN116867494A
(zh)
|
2021-02-15 |
2023-10-10 |
凯麦拉医疗公司 |
Irak4降解剂和其用途
|
|
MX2023009858A
(es)
|
2021-02-25 |
2023-09-12 |
Impact Biomedicines Inc |
Uso de inhibidores de proteina de bromodominio y motivo extraterminal (bet) solo o en combinacion con fedratinib o ruxolitinib como tratamiento para una malignidad hematologica tal como la mielofibrosis.
|
|
US11926625B2
(en)
|
2021-03-05 |
2024-03-12 |
Nimbus Saturn, Inc. |
HPK1 antagonists and uses thereof
|
|
AU2022243600A1
(en)
*
|
2021-03-26 |
2023-10-12 |
Sumitomo Pharma Oncology, Inc. |
Alk-5 inhibitors and uses thereof
|
|
WO2022203466A1
(ko)
*
|
2021-03-26 |
2022-09-29 |
주식회사 스탠다임 |
Lrrk2에 대해 저해 활성을 갖는 신규한 페닐아미노피리미딘 화합물 및 이의 용도
|
|
CN117355304A
(zh)
*
|
2021-03-26 |
2024-01-05 |
住友制药肿瘤公司 |
Alk-5抑制剂及其用途
|
|
WO2022213062A1
(en)
|
2021-03-29 |
2022-10-06 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
US12325697B2
(en)
|
2021-04-09 |
2025-06-10 |
Nimbus Clio, Inc. |
CBL-B modulators and uses thereof
|
|
WO2022221170A1
(en)
|
2021-04-12 |
2022-10-20 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
WO2022221866A1
(en)
|
2021-04-16 |
2022-10-20 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
KR20240020735A
(ko)
|
2021-05-07 |
2024-02-15 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Cdk2 분해제 및 그 용도
|
|
US11939331B2
(en)
|
2021-06-09 |
2024-03-26 |
Incyte Corporation |
Tricyclic heterocycles as FGFR inhibitors
|
|
CA3220155A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
CA3229560A1
(en)
|
2021-08-25 |
2023-03-02 |
Christopher L. Vandeusen |
Eif4e inhibitors and uses thereof
|
|
US12157732B2
(en)
|
2021-08-25 |
2024-12-03 |
PIC Therapeutics, Inc. |
eIF4E inhibitors and uses thereof
|
|
WO2023044297A1
(en)
|
2021-09-14 |
2023-03-23 |
Impact Biomedicines, Inc. |
Fedratinib for treating myeloproliferative disorders
|
|
EP4401735A4
(en)
*
|
2021-09-16 |
2025-07-16 |
Lomond Therapeutics Inc |
COMPOUNDS COMPRISING N-ARYLPYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC AGENTS
|
|
CA3236265A1
(en)
|
2021-10-29 |
2023-05-04 |
William Leong |
Irak4 degraders and synthesis thereof
|
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
CA3243560A1
(en)
|
2022-01-31 |
2023-08-03 |
Kymera Therapeutics, Inc. |
Iraqi Degradation Agents and Their Uses
|
|
EP4238564A1
(en)
*
|
2022-03-02 |
2023-09-06 |
Bash Biotech Inc |
New treatments of renal cell carcinoma
|
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
|
US11878958B2
(en)
|
2022-05-25 |
2024-01-23 |
Ikena Oncology, Inc. |
MEK inhibitors and uses thereof
|
|
IL318577A
(en)
|
2022-08-02 |
2025-03-01 |
Liminal Biosciences Ltd |
ARYL-TRIAZOLYL AND RELATED GPR84 ANTAGONISTS AND THEIR USES
|
|
KR20250056924A
(ko)
|
2022-08-02 |
2025-04-28 |
리미널 바이오사이언시스 리미티드 |
치환된 피리돈 gpr84 길항제 및 이의 용도
|
|
US20260028330A1
(en)
|
2022-08-02 |
2026-01-29 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
|
CN115745896B
(zh)
*
|
2022-11-18 |
2024-08-06 |
合肥医工医药股份有限公司 |
一种jak2激酶选择性抑制剂及其制备方法和用途
|
|
WO2024112894A1
(en)
|
2022-11-22 |
2024-05-30 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
EP4673149A1
(en)
*
|
2023-03-02 |
2026-01-07 |
Trustlife Global Inc. |
New compounds and treatment of renal cell carcinoma
|
|
AU2024312190A1
(en)
|
2023-06-23 |
2025-07-03 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
AU2024344754A1
(en)
|
2023-09-21 |
2026-04-02 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
|